Japanese Pharmacology & Therapeutics（JPT）
Vol. 26 No. 9 1998
* With abstract in English
Toxicity studies of CD-13(1)
－Single dose toxicity study of CD-13 in rats and beagle dogs－
K. Naohara, et al.
Jpn Pharmacol Ther 1998 26(9) 1333-43*
Toxicity studies of CD-13(2)
－Four week repeated dose oral toxicity study and 2-week ecovery study of CD-13 in male and female rats－
K. Naohara, et al.
Jpn Pharmacol Ther 1998 26(9) 1345-63*
Toxicity studies of CD-13(3)
－Four-week repeated dose oral toxicity study and 2-week recovery study of CD-13 in male and female beagle dogs－
K. Naohara, et al.
Jpn Pharmacol Ther 1998 26(9) 1365-91*
Reproductive and developmental toxicity studies of CD-13(1)
－Study of fertility and early embryonic development to implantation in rats－
K. Chihara, et al.
Jpn Pharmacol Ther 1998 26(9) 1393-400*
Reproductive and developmental toxicity studies of CD-13(2)
－Study for effects on embryo-fetal development in rats－
K. Chihara, et al.
Jpn Pharmacol Ther 1998 26(9) 1401-7*
Reproductive and developmental toxicity studies of CD-13(3)
－Study for effects on embryo-fetal development in rabbits－
K. Chihara, et al.
Jpn Pharmacol Ther 1998 26(9) 1409-17*
Reproductive and developmental toxicity studies of CD-13(4)
－Study for effects on prenatal and postnatal development, including maternal function－
K. Chihara, et al.
Jpn Pharmacol Ther 1998 26(9) 1419-34*
Effect of atorvastatin (YM548), a new HMG-CoA reductase inhibitor, on the regulation of cholesterol synthesis in HepG2 cells
T. Funatsu, et al.
Jpn Pharmacol Ther 1998 26(9) 1435-41
Upregulation of low density lipoprotein receptor activity and gene expression by atorvastatin (YM548), a new HMG-CoA reductase inhibitor,in HepG2 cells
T. Funatsu, et al.
Jpn Pharmacol Ther 1998 26(9) 1443-50
Time course of acute inhibition of cholesterol synthesis by YM548 in cholestylamine-primed rats
H. Tanaka, et al.
Jpn Pharmacol Ther 1998 26(9) 1451-4
Hypolipidemic effect of atorvastatin(YM548), a new HMG-CoA reductase inhibitor, in guinea pigs
T. Funatsu, et al.
Jpn Pharmacol Ther 1998 26(9) 1455-60
Effect of YM548, a New HMG-CoA reductase inhibitor, on lipid metabolism in normal guinea pig
H. Kakuta, et al.
Jpn Pharmacol Ther 1998 26(9) 1461-8
Triglyceride-lowering activity of novel HMG-CoA reductase inhibitor, YM548 in rats fed sucrose-rich diet
M. Suzuki, et al.
Jpn Pharmacol Ther 1998 26(9) 1469-74
Antiatherosclerotic effects of YM548 in Watanabe heritable hyperlipidemic rabbits
Y. Arai, et al.
Jpn Pharmacol Ther 1998 26(9) 1475-86
Effects of incadronate (YM175) on bone resorption and mineralization of cartilage in young rats
N. O'uchi, et al.
Jpn Pharmacol Ther 1998 26(9) 1487-92*
Basic study about the dosage and administration of NKH477, a novel cardiotonic drug
M. Hosono, et al.
Jpn Pharmacol Ther 1998 26(9) 1493-6
Effectiveness of NKH477 in the isolated guinea-pig heart with contractile dysfunction following post-ischemic reperfusion
T. Onda, et al.
Jpn Pharmacol Ther 1998 26(9) 1497-501
Oral mucosa irritation studies of hamsters and gastric mucosa irritation studies of rats
M. Kiguchi, et al.
Jpn Pharmacol Ther 1998 26(9) 1503-12*
Pharmaceutical development of irsogladine maleate tablets
Y. Matsuda, et al.
Jpn Pharmacol Ther 1998 26(9) 1513-7
Effects of ambroxol hydrochloride (Ponophen) on experimentally induced sinusitis in rabbits
M. Kondo, et al.
Jpn Pharmacol Ther 1998 26(9) 1519-28*
Protective effects against neuron damages, anti-fatigue and anti-stress effects of the herbal mixture, Juzen-taiho-to
T. Tsuda, et al.
Jpn Pharmacol Ther 1998 26(9) 1529-38*
Effects of terfenadine on sleeping time in electroencephalogram and electro-oculogram of rhesuses
C. Tateda, et al.
Jpn Pharmacol Ther 1998 26(9) 1539-43*
Early administration of the angiotensin-converting enzyme inhibitor imidapril attenuates ventricular remodeling after acute myocardial infarction
Y.Yoshitomi, et al.
Jpn Pharmacol Ther 1998 26(9) 1545-52*